Serum Institute of India

JetSynthesys Pvt. Ltd., a member of the JetLine Group of Companies, focuses on creating innovative digital products, platforms, and services aimed at enhancing the daily lives of users in India and beyond. The company is dedicated to developing technologies and content that cater to a wide audience, ensuring that its offerings resonate with diverse user needs. By leveraging powerful data analytics and delivering high-quality user experiences, JetSynthesys seeks to establish itself as a key player in the digital landscape. Through its commitment to excellence, the company aims to delight customers and foster engagement in the increasingly digital world.

Hervolution Therapeutics focuses on developing first-in-class immunotherapies to combat tumors from within. The company leverages Human Endogenous Retroviral proteins (HERVs) to create rationally designed immune therapeutics targeting the dark genome. Hervolution Therapeutics aims to address hidden enemies within the human body by pioneering innovative biotechnology solutions.

IntegriMedical is a global manufacturer specializing in original equipment for medical devices. The company focuses on the development and production of innovative needle-free drug delivery systems, specifically designed for patients who experience needle phobia. Utilizing advanced high-velocity jet stream technology, IntegriMedical's products administer RNA-based biologics and drugs through intramuscular and subcutaneous methods. These devices are engineered to enhance patient comfort and safety, significantly reducing pain associated with traditional injections. Compact and portable, IntegriMedical's solutions aim to facilitate ease of use for both patients and healthcare professionals.

Codagenix Inc., established in 2009 and headquartered in Farmingdale, New York, specializes in developing live-attenuated viral vaccines using its proprietary Synthetic Attenuated Virus Engineering (SAVE) platform. This technology involves the rational design of entire viral genomes via synthetic biology to create safe and effective vaccines for various human diseases such as influenza, dengue, respiratory syncytial virus, polio, and others. Additionally, Codagenix offers agricultural and companion animal vaccines.

Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in the research, development, and manufacturing of lentiviral vector and cell therapy products for various diseases. The company operates through two main segments: Platform and Product. Its LentiVector platform technology enables the integration of therapeutic genes into non-dividing cells, making it suitable for treating conditions affecting the brain and eyes. Oxford BioMedica's product pipeline includes several candidates in various stages of development, targeting diseases such as hematological tumors, age-related macular degeneration, and central nervous system disorders. Additionally, the company has established partnerships with notable firms like Novartis and Bristol Myers Squibb to advance its therapeutic offerings. Oxford BioMedica also focuses on growing its bioprocessing services, leveraging its technologies to provide revenue-generating solutions for third-party clients, while continuing to innovate in gene and cell therapy. Founded in 1995, the company has positioned itself as a leader in the field of gene therapy, addressing unmet medical needs through its advanced therapeutic candidates.

SCHOTT Poonawalla is a manufacturer based in Mumbai, India, specializing in pharmaceutical packaging solutions made from neutral glass tubing. The company produces a diverse array of products for the pharmaceutical industry, including vials, pre-fillable syringes, ampoules, and cartridges. With a focus on parenteral packaging systems, SCHOTT Poonawalla provides essential containers that meet the stringent requirements of the pharmaceutical sector, ensuring the safe and effective delivery of medications.

X-Vax Technology is a biotechnology company established in 2015 and headquartered in Jupiter, Florida. Its primary focus is the preclinical and clinical development of vaccines targeting mucosal infections caused by pathogens, including herpes, influenza, tuberculosis, and HIV, which affect millions globally. X-Vax is known for its development of a herpes vaccine candidate based on a genetically altered HSV-2 virus, specifically designed to elicit a robust immune response by inducing antibodies that lead to the killing of infected cells. This innovative approach utilizes Fc receptor activating antibodies that facilitate antibody-dependent cell-mediated killing, aiming to provide effective protection against herpes types 1 and 2. Through its pioneering research, X-Vax intends to advance the field of vaccines and enhance immune responses against significant viral infections.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

Nanotherapeutics is a privately held specialty biopharmaceutical company with full product development, cGMP manufacturing capabilities, and a proprietary pipeline. The Company's technologies can be used with all drug types ranging from small molecules to proteins and peptides. These technologies can be employed with new chemical entities or with generic drugs and can be used with the spectrum of existing drug types ranging from small synthetic molecules to large recombinant macromolecules.